PortalPublikationenRisk factors for symptom relapse in collagenous colitis afte...

Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy

Standard

Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy. / Miehlke, Stephan; Hansen, Jesper B; Madisch, Ahmed; Schwarz, Franca; Kuhlisch, Eberhard; Morgner, Andrea; Teglbjaerg, Peter S; Vieth, Michael; Aust, Daniela; Bonderup, Ole K.

in: INFLAMM BOWEL DIS, Jahrgang 19, Nr. 13, 12.2013, S. 2763-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Miehlke, S, Hansen, JB, Madisch, A, Schwarz, F, Kuhlisch, E, Morgner, A, Teglbjaerg, PS, Vieth, M, Aust, D & Bonderup, OK 2013, 'Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy', INFLAMM BOWEL DIS, Jg. 19, Nr. 13, S. 2763-7. https://doi.org/10.1097/01.MIB.0000438135.88681.98

APA

Miehlke, S., Hansen, J. B., Madisch, A., Schwarz, F., Kuhlisch, E., Morgner, A., Teglbjaerg, P. S., Vieth, M., Aust, D., & Bonderup, O. K. (2013). Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy. INFLAMM BOWEL DIS, 19(13), 2763-7. https://doi.org/10.1097/01.MIB.0000438135.88681.98

Vancouver

Miehlke S, Hansen JB, Madisch A, Schwarz F, Kuhlisch E, Morgner A et al. Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy. INFLAMM BOWEL DIS. 2013 Dez;19(13):2763-7. https://doi.org/10.1097/01.MIB.0000438135.88681.98

Bibtex

@article{3b52596d33904e29b39d428465b24ebc,
title = "Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy",
abstract = "BACKGROUND: Oral budesonide has been proven effective in short- and long-term treatment of collagenous colitis; however, symptom relapse frequently occurs after drug withdrawal. The aim of this study was to identify the risk factors for symptom relapse in patients with collagenous colitis after withdrawal of short-term budesonide therapy.METHODS: One hundred twenty-three patients from 4 randomized controlled studies who achieved clinical remission after short-term treatment with budesonide (9 mg/d) were analyzed, including 40 patients receiving subsequent budesonide maintenance therapy (6 mg/d) for 6 months and 83 patients without active maintenance treatment. Variables available for analysis were age, sex, baseline stool frequency, duration of diarrhea, collagenous band thickness, and lamina propria inflammation. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated by Cox proportional hazard model.RESULTS: The overall symptom relapse rate was 61%. By multivariate analysis, a baseline stool frequency >5 per day (HR, 3.95; 95% CI, 1.08-14.39), history of diarrhea >12 months (HR, 1.77; 95% CI, 1.04-3.03), and the absence of budesonide maintenance therapy (HR, 2.71; 95% CI, 1.37-5.38) were associated with symptom relapse. The time to relapse was shorter in patients with a baseline stool frequency >5 per day (56 versus 199 d, P = 0.024), as in those with history of diarrhea >12 months (56 versus 220 d, P = 0.009). Budesonide maintenance therapy delayed the time to relapse (56 versus 207 d, P = 0.005).CONCLUSIONS: Our data demonstrate that a high stool frequency at baseline and a long duration of diarrhea are risk factors for symptom relapse in collagenous colitis, whereas budesonide maintenance therapy is a protective factor against symptom relapse.",
keywords = "Anti-Inflammatory Agents, Budesonide, Colitis, Collagenous, Diarrhea, Female, Follow-Up Studies, Humans, Inflammation, Male, Middle Aged, Prognosis, Randomized Controlled Trials as Topic, Recurrence, Risk Factors, Substance Withdrawal Syndrome, Journal Article",
author = "Stephan Miehlke and Hansen, {Jesper B} and Ahmed Madisch and Franca Schwarz and Eberhard Kuhlisch and Andrea Morgner and Teglbjaerg, {Peter S} and Michael Vieth and Daniela Aust and Bonderup, {Ole K}",
year = "2013",
month = dec,
doi = "10.1097/01.MIB.0000438135.88681.98",
language = "English",
volume = "19",
pages = "2763--7",
journal = "INFLAMM BOWEL DIS",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "13",

}

RIS

TY - JOUR

T1 - Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy

AU - Miehlke, Stephan

AU - Hansen, Jesper B

AU - Madisch, Ahmed

AU - Schwarz, Franca

AU - Kuhlisch, Eberhard

AU - Morgner, Andrea

AU - Teglbjaerg, Peter S

AU - Vieth, Michael

AU - Aust, Daniela

AU - Bonderup, Ole K

PY - 2013/12

Y1 - 2013/12

N2 - BACKGROUND: Oral budesonide has been proven effective in short- and long-term treatment of collagenous colitis; however, symptom relapse frequently occurs after drug withdrawal. The aim of this study was to identify the risk factors for symptom relapse in patients with collagenous colitis after withdrawal of short-term budesonide therapy.METHODS: One hundred twenty-three patients from 4 randomized controlled studies who achieved clinical remission after short-term treatment with budesonide (9 mg/d) were analyzed, including 40 patients receiving subsequent budesonide maintenance therapy (6 mg/d) for 6 months and 83 patients without active maintenance treatment. Variables available for analysis were age, sex, baseline stool frequency, duration of diarrhea, collagenous band thickness, and lamina propria inflammation. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated by Cox proportional hazard model.RESULTS: The overall symptom relapse rate was 61%. By multivariate analysis, a baseline stool frequency >5 per day (HR, 3.95; 95% CI, 1.08-14.39), history of diarrhea >12 months (HR, 1.77; 95% CI, 1.04-3.03), and the absence of budesonide maintenance therapy (HR, 2.71; 95% CI, 1.37-5.38) were associated with symptom relapse. The time to relapse was shorter in patients with a baseline stool frequency >5 per day (56 versus 199 d, P = 0.024), as in those with history of diarrhea >12 months (56 versus 220 d, P = 0.009). Budesonide maintenance therapy delayed the time to relapse (56 versus 207 d, P = 0.005).CONCLUSIONS: Our data demonstrate that a high stool frequency at baseline and a long duration of diarrhea are risk factors for symptom relapse in collagenous colitis, whereas budesonide maintenance therapy is a protective factor against symptom relapse.

AB - BACKGROUND: Oral budesonide has been proven effective in short- and long-term treatment of collagenous colitis; however, symptom relapse frequently occurs after drug withdrawal. The aim of this study was to identify the risk factors for symptom relapse in patients with collagenous colitis after withdrawal of short-term budesonide therapy.METHODS: One hundred twenty-three patients from 4 randomized controlled studies who achieved clinical remission after short-term treatment with budesonide (9 mg/d) were analyzed, including 40 patients receiving subsequent budesonide maintenance therapy (6 mg/d) for 6 months and 83 patients without active maintenance treatment. Variables available for analysis were age, sex, baseline stool frequency, duration of diarrhea, collagenous band thickness, and lamina propria inflammation. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated by Cox proportional hazard model.RESULTS: The overall symptom relapse rate was 61%. By multivariate analysis, a baseline stool frequency >5 per day (HR, 3.95; 95% CI, 1.08-14.39), history of diarrhea >12 months (HR, 1.77; 95% CI, 1.04-3.03), and the absence of budesonide maintenance therapy (HR, 2.71; 95% CI, 1.37-5.38) were associated with symptom relapse. The time to relapse was shorter in patients with a baseline stool frequency >5 per day (56 versus 199 d, P = 0.024), as in those with history of diarrhea >12 months (56 versus 220 d, P = 0.009). Budesonide maintenance therapy delayed the time to relapse (56 versus 207 d, P = 0.005).CONCLUSIONS: Our data demonstrate that a high stool frequency at baseline and a long duration of diarrhea are risk factors for symptom relapse in collagenous colitis, whereas budesonide maintenance therapy is a protective factor against symptom relapse.

KW - Anti-Inflammatory Agents

KW - Budesonide

KW - Colitis, Collagenous

KW - Diarrhea

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Inflammation

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Randomized Controlled Trials as Topic

KW - Recurrence

KW - Risk Factors

KW - Substance Withdrawal Syndrome

KW - Journal Article

U2 - 10.1097/01.MIB.0000438135.88681.98

DO - 10.1097/01.MIB.0000438135.88681.98

M3 - SCORING: Journal article

C2 - 24216688

VL - 19

SP - 2763

EP - 2767

JO - INFLAMM BOWEL DIS

JF - INFLAMM BOWEL DIS

SN - 1078-0998

IS - 13

ER -